Estradiol (Evorel 50)
Is It Right for You?
A complete guide to Estradiol (Evorel 50) — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Evorel 50 (Estradiol Transdermal Patch)?
Evorel 50 is a hormone replacement therapy (HRT) product delivering estradiol — the primary naturally occurring human oestrogen — through a self-adhesive patch applied to the skin. Each Evorel 50 patch contains 3.2 mg of estradiol and releases approximately 50 micrograms of estradiol per 24 hours through the skin into the systemic circulation. Each patch is worn for 3 to 4 days before being replaced, meaning two patches are applied per week.
Transdermal estradiol patches offer significant clinical advantages over oral oestrogen preparations. By bypassing first-pass hepatic metabolism (which converts oral estradiol to less potent metabolites and triggers hepatic protein synthesis), transdermal estradiol delivers natural estradiol directly into the bloodstream at consistent, physiological concentrations. This route is associated with a significantly lower risk of venous thromboembolism compared to oral oestrogen, as the liver is not stimulated to produce prothrombotic clotting factors. It is also not associated with the elevation of triglycerides seen with oral oestrogens.
The Evorel range includes multiple strengths (Evorel 25, 50, 75, 100) representing different estradiol release rates, allowing flexible dose titration to manage menopausal symptoms optimally.
Evorel 50 is a prescription-only medication in the UK. A licensed clinician must assess your symptoms, medical history, contraindications, and progestogen requirements before prescribing — which can now be done quickly and conveniently through a telehealth consultation.
What Conditions Is Evorel 50 Used For?
Evorel 50 is prescribed for:
relief of vasomotor symptoms (hot flushes, night sweats), urogenital atrophy (vaginal dryness, dyspareunia, urinary symptoms), sleep disturbance, mood changes, and cognitive symptoms associated with oestrogen deficiency at menopause.
HRT with oestrogen reduces bone resorption and significantly reduces fracture risk in post-menopausal women; it is particularly beneficial for women with early menopause or osteoporosis at high fracture risk.
oestrogen replacement in women who experience menopause before age 40, where HRT is essential for bone protection, cardiovascular protection, and symptom management.
oestrogen replacement following bilateral oophorectomy (ovary removal).
Unopposed oestrogen therapy (oestrogen without a progestogen) in women who have a uterus significantly increases the risk of endometrial hyperplasia and endometrial cancer. Women with an intact uterus must take a progestogen alongside Evorel to protect the endometrium. Your clinician will prescribe an appropriate progestogen (such as Cyclogest, Utrogestan, or a Mirena coil). Women who have had a hysterectomy can use oestrogen-only HRT without progestogen.
How Does Evorel 50 Work?
Estradiol released from the Evorel patch diffuses through the skin into the capillary circulation, entering the systemic bloodstream as native estradiol (17β-estradiol) without hepatic first-pass modification. Estradiol binds to oestrogen receptors (ERα and ERβ) — nuclear receptors present in many tissues including the hypothalamus, uterus, breast, bone, cardiovascular system, urogenital tract, skin, and brain.
In the hypothalamus, oestrogen suppresses the dysregulated GnRH pulsatility that underlies hot flushes, restoring thermoregulatory stability. In the urogenital tract, oestrogen maintains epithelial thickness, lubrication, and tissue integrity, reversing the atrophic changes of menopause. In bone, oestrogen inhibits osteoclast-mediated bone resorption, preserving bone mineral density and reducing fracture risk. In the cardiovascular system (in younger post-menopausal women), oestrogen has favourable effects on lipid profiles, endothelial function, and arterial elasticity.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Apply the patch to clean, dry, intact skin on the lower abdomen, buttock, or upper hip — below the waistline. Avoid the breast area, waistband, and skin folds.
Press firmly for 10 seconds, ensuring all edges adhere fully to the skin.
Rotate application sites — do not apply to the same spot consecutively to avoid skin irritation.
Change patches on the same two days each week (e.g. Monday and Thursday) for consistent hormone levels.
Avoid applying to irritated, damaged, or broken skin, recently shaved skin, or skin exposed to sunscreen or body lotion.
Swimming, bathing, and showering are fine with the patch applied — most patients find patches adhere well during normal activities, though vigorous towelling or saunas may affect adhesion.
If a patch falls off, apply a new one to a fresh site and continue on your normal change day schedule.
Side Effects of Evorel 50
Side effects from transdermal estradiol are generally fewer and milder than with oral oestrogen. Most women tolerate the patches well.
- Skin reactions at application site — redness, itching, irritation (most common; rotating sites reduces this)
- Breast tenderness or swelling
- Headache
- Nausea (less common than oral oestrogen)
- Bloating
- Mood changes
- Breakthrough bleeding or spotting (particularly in the first 3 to 6 months)
- Venous thromboembolism (VTE) — risk is significantly lower with transdermal than oral oestrogen, but not zero; seek immediate care for unilateral leg swelling, calf pain, or breathlessness
- Breast cancer — oestrogen-progestogen combined HRT is associated with a small increased risk of breast cancer with prolonged use (> 5 years); oestrogen-only HRT carries a different, smaller risk profile
- Cardiovascular events — transdermal oestrogen in women under 60 or within 10 years of menopause is generally cardioprotective; risk may increase in older women with pre-existing cardiovascular disease
- Endometrial hyperplasia / cancer — if progestogen is inadequately provided in women with a uterus
This is a clinically important distinction. Oral oestrogen significantly increases VTE risk (approximately doubling it) through hepatic stimulation of clotting factors. Transdermal oestrogen (such as Evorel patches) bypasses this hepatic effect and does not significantly increase VTE risk above baseline. For women at increased VTE risk (obesity, history of VTE, thrombophilia), transdermal oestrogen is strongly preferred over oral preparations.
Drug Interactions
Always disclose all medications to your clinician and pharmacist.
Significantly accelerate oestrogen metabolism, reducing serum estradiol levels and symptom control. Higher patch strengths may be needed; discuss with your clinician.
Oestrogen-containing HRT may reduce lamotrigine plasma levels; seizure threshold monitoring is important in women with epilepsy starting HRT.
Oestrogen increases thyroid-binding globulin, potentially requiring upward adjustment of levothyroxine dose in hypothyroid women starting HRT.
Important Warnings
Women with an intact uterus must always use HRT as combined therapy (oestrogen plus progestogen). Using Evorel patches without an adequate progestogen in women with a uterus risks endometrial hyperplasia and uterine cancer.
Combined oestrogen-progestogen HRT is associated with a small increased risk of breast cancer that becomes relevant after approximately 5 years of use. The absolute risk is modest — equivalent to the risk of drinking 1 to 2 units of alcohol per day. The type of progestogen matters; micronised progesterone (Cyclogest/Utrogestan) appears to carry a lower breast cancer risk than synthetic progestins. Regular breast screening (NHS mammography programme) should be maintained.
Current evidence supports the "window of opportunity" concept: HRT started within 10 years of menopause or before age 60 is associated with cardiovascular benefits or neutral effects. Starting HRT more than 10 to 20 years after menopause in older women may carry a small increase in cardiovascular risk. For most symptomatic perimenopausal or recently post-menopausal women, HRT is safe and beneficial.
Evorel 50 is contraindicated in: current or recent breast or endometrial cancer, undiagnosed vaginal bleeding, active or recent VTE, active liver disease, known or suspected oestrogen-sensitive tumours, or pregnancy.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Evorel 50 FAQs
Oral oestrogen is absorbed from the gut and travels directly to the liver via the portal vein, where it stimulates the production of clotting factors, raising VTE risk. Transdermal oestrogen (patches, gels, sprays) delivers estradiol directly into the systemic circulation via the skin, bypassing the liver entirely. This means no hepatic stimulation of clotting factors, and VTE risk is not significantly increased above baseline. For women with risk factors for blood clots — including obesity, strong family history of VTE, or thrombophilia — transdermal HRT is strongly preferred.
No — women who have had a total hysterectomy (removal of the uterus) do not have an endometrium to protect and can safely use oestrogen-only HRT such as Evorel patches without any progestogen. This simplifies the HRT regimen and avoids progestogen-related side effects.
The decision about duration of HRT is individual. For most women using HRT for symptom management, treatment for 5 years is considered low risk with significant quality-of-life benefit. Many women choose to continue for longer, particularly those with premature ovarian insufficiency, strong osteoporosis risk, or ongoing symptoms. Current guidance recommends regular (at least annual) review of the benefits and risks with your clinician. There is no absolute maximum duration; it is a personal decision made with medical guidance.
Skin irritation at the application site is the most common local side effect of patches. Strategies include: always rotating sites between the four approved areas (lower abdomen, buttocks, upper hip), never applying to the same spot consecutively, ensuring skin is clean and completely dry before application, avoiding products like creams and oils on the application site, and gently pressing the patch for 10 seconds to ensure full adhesion. If irritation persists despite these measures, your clinician may suggest switching to a gel or spray formulation, which some women find better tolerated.